Curis will receive $8 million in milestone payments from its Swiss partner Debiopharm after French authorities approved a CTA for a study of Debio 0932, a potential treatment for tumors. Debiopharm plans to begin an open-label, multi-center dose-escalation Phase I trial evaluating the safety of Debio 0932 during the first quarter of the year in patients suffering from advanced solid tumors or lymphoma.
"We believe that Debio 0932 may have broad potential in a number of cancer indications," Dan Passeri, Curis' president and chief executive, says in a statement. "The acceptance by the French regulatory authorities of Debiopharm's CTA package is an important milestone in the development of this innovative cancer treatment and a testimony to Debiopharm's regulatory expertise and commitment to Debio 0932," he adds.
Curis also is partnering with Genentech to develop meds to treat metastatic colorectal cancer and metastatic basal cell carcinoma.
- check out Curis' release